Management and Outcomes of Stroke Patients with Atrial Fibrillation in the Non-VKA Oral AntiCoagulant Era
Not Applicable
Recruiting
- Conditions
- Diseases of the nervous system
- Registration Number
- KCT0004033
- Lead Sponsor
- Bayer Korea
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 3000
Inclusion Criteria
1. Adult (Age > 18) female and male patients diagnosed with acute ischemic stroke patients admitted to the participating centers within 7 days after onset (the time of first recognition of stroke symptoms)
2. Patients who were diagnosed for any type of AF by history or documented during hospitalization
3. Relevant ischemic lesions documented on diffusion-weighted imaging (DWI)
Exclusion Criteria
Patients who refused to participate in this study or to give an informed consent
Study & Design
- Study Type
- Observational Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Incidence rate of a composite event of recurrent stroke, myocardial infarction, and all kinds of death
- Secondary Outcome Measures
Name Time Method incidence rate of a composite event of recurrent stroke, myocardial infarction, and vascular death;Stroke recurrence;Stroke recurrence;Myocardial infarction or hospitalization for unstable angina or coronary revascularization;All kinds of death;Any invasive procedures considering temporary suspention of antithrombotic medication;Major bleeding;Symptomatic hemorrhagic transformation of the primary ischemic lesion